Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Gyre Therapeutics, Inc. (CBIO) AI Forecast

Our AI analyzed Gyre Therapeutics, Inc.. Create a free account to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$CBIO Neutral Signal Full forecast available
Sign Up Free

Gyre Therapeutics, Inc. (CBIO) Stock Forecast 2025

Gyre Therapeutics, Inc. (CBIO) AI Stock Price Forecast & Investment Analysis

Gyre Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Gyre Therapeutics, Inc. (CBIO) - Comprehensive Stock Analysis & Investment Research

Deep dive into Gyre Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 26, 2026, 11:56 p.m. (UTC)

Gyre Therapeutics, Inc. Investment Summary

When evaluating whether Gyre Therapeutics, Inc. (CBIO) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Gyre Therapeutics, Inc. (CBIO) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $602 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Gyre Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Gyre Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Gyre Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Gyre Therapeutics, Inc.

Sign Up Free
Corporate Identity

Gyre Therapeutics, Inc. (Stock Symbol: CBIO) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Gyre Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Gyre Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Gyre Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Gyre Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis

Gyre Therapeutics, Inc. generates annual revenues of $117 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Gyre Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Gyre Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Gyre Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Gyre Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Gyre Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Gyre Therapeutics, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Gyre Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company shows positive operational efficiency through free cash flow generation of $3 million annually . Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.

Asset Utilization Efficiency

Asset turnover ratio of 0.72x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Gyre Therapeutics, Inc. (CBIO) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Gyre Therapeutics, Inc. stock analysis.

Deep dive into Gyre Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Gyre Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Gyre Therapeutics, Inc.:

P/B Ratio 5.95x
Market Cap $602M
EPS $1.98
Book Value/Share $2.74
Revenue/Share $3.17
FCF/Share $0.08
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Gyre Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Gyre Therapeutics, Inc.: An ROE of 40.8% demonstrates excellent shareholder value creation.

ROE 40.8%
ROA 25.5%
Operating Margin 16.3%
Net Margin 17.3%
EBT Margin -3.8%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Gyre Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Gyre Therapeutics, Inc.:

D/E Ratio 0.25x
Financial Leverage 1.60x
Interest Coverage 0.1x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Gyre Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Gyre Therapeutics, Inc.: Free cash flow of $3M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow -$180M
Free Cash Flow $3M
Capital Spending $184M
FCF/Sales 2.6%
CapEx/Sales 156.8%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Gyre Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Gyre Therapeutics, Inc.: An asset turnover of 0.72x suggests room for improvement in asset utilization.

Asset Turnover 0.72x
Understanding Financial Statement Data

What these metrics mean: Key figures from Gyre Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Gyre Therapeutics, Inc.: With annual revenue of $117M, Gyre Therapeutics, Inc. demonstrates solid business size.

Income Statement
Total Revenue $117M
Operating Income $38M
Net Income $41M
R&D Expense $175M
Balance Sheet Highlights (% Of Assets)
Total Liabilities 25%
Dividend & Shareholder Information
Shares Outstanding 37M
Growth Metrics (YoY)
Net Income Growth 17.3%
EPS Growth 12.2%

Latest Gyre Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Gyre Therapeutics, Inc. (CBIO) stock price and investment outlook.

More news available

Sign up free to read all 7 news articles and stay updated on market developments.

Sign Up Free to Read More

Gyre Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Gyre Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Aardvark Therapeutics, Inc. AARD ██% $139M x 1.6x
Abbvie Inc. ABBV ██% $454.75B 125.1x x
Abcellera Biologics Inc. ABCL ██% $1.72B x 1.8x
Abeona Therapeutics Inc. ABEO ██% $363M 5.5x 2.5x
Abbott Laboratories ABT ██% $175.49B 28.0x 3.4x
Arbutus Biopharma Corp ABUS ██% $880M 5.5x 3.4x
Abvc Biopharma, Inc. ABVC ██% $31M x 2.9x
Abivax S.A. ABVX ██% $10.30B x x
Acadia Pharmaceuticals Inc ACAD ██% $4.25B 11.3x 3.4x
Adicet Bio, Inc. ACET ██% $79M x 0.6x
Aclaris Therapeutics, Inc. ACRS ██% $765M x 5.3x
Acrivon Therapeutics, Inc. ACRV ██% $65M x 0.7x
Accustem Sciences Inc. ACUT ██% $3M x x
Acurx Pharmaceuticals, Inc. ACXP ██% $6M x 0.9x
Adagene Inc. ADAG ██% $199M x 5.2x
Adc Therapeutics Sa ADCT ██% $155M x x
Adial Pharmaceuticals, Inc. ADIL ██% $6M x 1.6x
Aditxt, Inc. ADTX ██% $4M x x
Addex Therapeutics Ltd. ADXN ██% $7M x x
Aeon Biopharma, Inc. AEON ██% $11M x x
Agios Pharmaceuticals, Inc. AGIO ██% $2.15B x 1.9x
Akebia Therapeutics, Inc. AKBA ██% $327M x 11.9x
Akari Therapeutics Plc AKTX ██% $16M x 1.1x
Aldeyra Therapeutics, Inc. ALDX ██% $94M x 2.2x
Alkermes Plc. ALKS ██% $8.82B 57.7x 5.0x
Allarity Therapeutics, Inc. ALLR ██% $19M x 2.8x
Alumis Inc. ALMS ██% $3.54B x 6.2x
Alnylam Pharmaceuticals, Inc. ALNY ██% $35.57B 113.4x 45.1x
Altimmune, Inc. ALT ██% $552M x 2.0x
Alx Oncology Holdings Inc ALXO ██% $272M x 1.8x
Alzamend Neuro, Inc. ALZN ██% $5M x 7.3x
Amylyx Pharmaceuticals, Inc. AMLX ██% $1.95B x 7.2x
Amphastar Pharmaceuticals, Inc. AMPH ██% $842M 10.6x 1.1x
Amarin Corp Plc\Uk AMRN ██% $285M x 0.6x
Amneal Pharmaceuticals, Inc. AMRX ██% $5.68B 46.5x x
Anaptysbio, Inc ANAB ██% $1.59B x 125.1x
Anebulo Pharmaceuticals, Inc. ANEB ██% $12M x 1.6x
Ani Pharmaceuticals Inc ANIP ██% $1.64B 17.8x 2.9x
Anixa Biosciences Inc ANIX ██% $127M x 8.8x
Annexon, Inc. ANNX ██% $807M x 4.0x
Alto Neuroscience, Inc. ANRO ██% $941M x 3.9x
An2 Therapeutics, Inc. ANTX ██% $177M x 2.2x
Annovis Bio, Inc. ANVS ██% $74M x 23.8x
Apollomics Inc. APLM ██% $41M x x
Aprea Therapeutics, Inc. APRE ██% $8M x 0.2x
Apimeds Pharmaceuticals Us, Inc. APUS ██% $8M x 0.1x
Aptevo Therapeutics Inc. APVO ██% $5M x 0.5x
Aquestive Therapeutics, Inc. AQST ██% $469M x x
Arcturus Therapeutics Holdings Inc. ARCT ██% $165M x 0.9x
Ardelyx, Inc. ARDX ██% $1.27B x 8.5x
Arcutis Biotherapeutics, Inc. ARQT ██% $3.42B x 18.0x
Artelo Biosciences, Inc. ARTL ██% $4M x 0.6x
Arvinas, Inc. ARVN ██% $524M x 1.4x
Arrowhead Pharmaceuticals, Inc. ARWR ██% $12.20B x 19.9x
Aspire Biopharma Holdings, Inc. ASBP ██% $9M x 2.4x
Assembly Biosciences, Inc. ASMB ██% $500M x 2.5x
Ascendis Pharma A/S ASND ██% $15.66B x x
Assertio Holdings, Inc. ASRT ██% $151M x 2.0x
Atai Beckley N.V. ATAI ██% $2.65B x 16.6x
Alterity Therapeutics Ltd ATHE ██% $85M x x
Actinium Pharmaceuticals, Inc. ATNM ██% $28M x 12.1x
Atossa Therapeutics, Inc. ATOS ██% $21M x 0.7x
Avenue Therapeutics, Inc. ATXI ██% $910K x 0.8x
Aurinia Pharmaceuticals Inc. AUPH ██% $1.99B 6.7x 3.5x
Arrivent Biopharma, Inc. AVBP ██% $1.43B x 4.4x
Atea Pharmaceuticals, Inc. AVIR ██% $380M x 1.6x
Avalo Therapeutics, Inc. AVTX ██% $940M x 13.8x
Axim Biotechnologies, Inc. AXIM ██% $1M x x
Axsome Therapeutics, Inc. AXSM ██% $12.42B x 227.5x
Azitra, Inc. AZTR ██% $2M x 0.2x
Bridgebio Pharma, Inc. BBIO ██% $16.23B x x
Bridgebio Oncology Therapeutics, Inc. BBOT ██% $698M x 1.9x
Bicara Therapeutics Inc. BCAX ██% $1.82B x 3.5x
Briacell Therapeutics Corp. BCTX ██% $32M x 1.3x
Bicycle Therapeutics Plc BCYC ██% $290M x 0.5x
Bioadaptives, Inc. BDPT ██% $10K x x
Biodexa Pharmaceuticals Plc BDRX ██% $2M x x
Bullfrog Ai Holdings, Inc. BFRG ██% $11M x 2.3x
Biofrontera Inc. BFRI ██% $13M x 2.1x
Bausch Health Companies Inc. BHC ██% $1.66B x x
Bioharvest Sciences Inc. BHST ██% $45M x 1.8x
Bioage Labs, Inc. BIOA ██% $972M x 2.6x
Bio Essence Corp BIOE ██% $13M 9.7x x
Sb Technology Holdings, Inc. BIOM ██% $510K x x
Biovie Inc. BIVI ██% $11M x 0.7x
Bioxytran, Inc BIXT ██% $3M x x
Biolinerx Ltd. BLRX ██% $13M x x
Belite Bio, Inc BLTE ██% $6.15B x 8.0x
Biomea Fusion, Inc. BMEA ██% $91M x 4.9x
Biomarin Pharmaceutical Inc BMRN ██% $11.38B 42.3x 1.8x
Bristol Myers Squibb Co BMY ██% $125.36B 17.2x 6.3x
Benitec Biopharma Inc. BNTC ██% $393M x 2.1x
Boundless Bio, Inc. BOLD ██% $56M x 0.7x
Bolt Biotherapeutics, Inc. BOLT ██% $7M x 0.4x
Bio-Path Holdings, Inc. BPTH ██% $2M x x
Bioquest Corp BQST ██% $2M x x
Barinthus Biotherapeutics Plc. BRNS ██% $25M x 0.4x
Bespoke Extracts, Inc. BSPK ██% $10K x x
Bioxcel Therapeutics, Inc. BTAI ██% $24M x x
Beyondspring Inc. BYSI ██% $44M x x
Calcimedica, Inc. CALC ██% $11M x x
Can-Fite Biopharma Ltd. CANF ██% $7M x 1.2x
Capricor Therapeutics, Inc. CAPR ██% $1.14B x 4.1x
Perspective Therapeutics, Inc. CATX ██% $336M x 1.0x
Gyre Therapeutics, Inc. CBIO ██% $602M x 6.0x
Cdt Equity Inc. CDT ██% $2M x x
Cingulate Inc. CING ██% $62M x 3.3x
Cell Source, Inc. CLCS ██% $65M x x
Clene Inc. CLNN ██% $63M x x
Cellectar Biosciences, Inc. CLRB ██% $20M x 5.9x
Clearside Biomedical, Inc. CLSDQ ██% $1M x x
Climb Bio, Inc. CLYM ██% $735M x 5.0x
Chemomab Therapeutics Ltd. CMMB ██% $10M x 0.8x
Clearmind Medicine Inc. CMND ██% $2M x x
Compass Pathways Plc CMPS ██% $1.52B x 4.7x
Cnbx Pharmaceuticals Inc. CNBX ██% N/A x x
Cns Pharmaceuticals, Inc. CNSP ██% $8M x 108.1x
Centessa Pharmaceuticals Plc CNTA ██% $6.27B x 12.9x
Connect Biopharma Holdings Ltd CNTB ██% $134M x 3.2x
Context Therapeutics Inc. CNTX ██% $56M x 1.1x
Cocrystal Pharma, Inc. COCP ██% $13M x 3.1x
Cogent Biosciences, Inc. COGT ██% $6.79B x 11.2x
Collegium Pharmaceutical, Inc COLL ██% $1.15B 15.4x 3.7x
Corcept Therapeutics Inc CORT ██% $9.96B 210.4x 15.6x
Coya Therapeutics, Inc. COYA ██% $103M x 2.1x
China Pharma Holdings, Inc. CPHI ██% $62M x 1.7x
Cumberland Pharmaceuticals Inc CPIX ██% $105M x 4.8x
Cannapharmarx, Inc. CPMD ██% $1M x x
Catalyst Pharmaceuticals, Inc. CPRX ██% $3.85B 17.4x 3.8x
Corbus Pharmaceuticals Holdings, Inc. CRBP ██% $163M x 1.3x
Cormedix Inc. CRMD ██% $617M 3.4x 1.4x
Crinetics Pharmaceuticals, Inc. CRNX ██% $8.82B x 6.9x
Cervomed Inc. CRVO ██% $25M x 2.3x
Corvus Pharmaceuticals, Inc. CRVS ██% $1.10B x 4.6x
Cytomx Therapeutics, Inc. CTMX ██% $705M x 2.2x
Contineum Therapeutics, Inc. CTNM ██% $525M x 2.1x
Citius Oncology, Inc. CTOR ██% $52M x 1.5x
Ctt Pharmaceutical Holdings, Inc. CTTH ██% $4M x 4.9x
Citius Pharmaceuticals, Inc. CTXR ██% $15M x 0.2x
Cue Biopharma, Inc. CUE ██% $139M x 6.4x
Curanex Pharmaceuticals Inc CURX ██% $5M x 0.7x
Cadrenal Therapeutics, Inc. CVKD ██% $6M x 3.5x
Cv Sciences, Inc. CVSI ██% $4M x 3.0x
Cyclerion Therapeutics, Inc. CYCN ██% $15M x 2.2x
Cytodyn Inc. CYDY ██% $272M x x
Cypherpunk Technologies Inc. CYPH ██% $66M x 0.8x
Cryoport, Inc. CYRX ██% $805M 10.1x 1.6x
Cytokinetics Inc CYTK ██% $10.96B x x
Dare Bioscience, Inc. DARE ██% $19M x 25.4x
Decoy Therapeutics Inc. DCOY ██% $3M x 0.7x
Journey Medical Corp DERM ██% $169M x 5.5x
Diamedica Therapeutics Inc. DMAC ██% $367M x 7.8x
Damora Therapeutics, Inc. DMRA ██% $1.80B x 3.5x
Dianthus Therapeutics, Inc. /De/ DNTH ██% $5.67B x 4.7x
Dermata Therapeutics, Inc. DRMA ██% $5M x 0.8x
Bright Minds Biosciences Inc. DRUG ██% $700M x x
Design Therapeutics, Inc. DSGN ██% $736M x 3.4x
Dogwood Therapeutics, Inc. DWTX ██% $50M x 0.6x
Dyne Therapeutics, Inc. DYN ██% $4.04B x 4.7x
Emergent Biosolutions Inc. EBS ██% $376M x 0.7x
Edesa Biotech, Inc. EDSA ██% $47M x 4.6x
Pmgc Holdings Inc. ELAB ██% $4M x 0.3x
Elanco Animal Health Inc ELAN ██% $12.44B x 1.9x
Eledon Pharmaceuticals, Inc. ELDN ██% $272M x 6.1x
Elite Pharmaceuticals Inc /Nv/ ELTP ██% $418M 9.3x 4.2x
Elicio Therapeutics, Inc. ELTX ██% $79M x x
Enliven Therapeutics, Inc. ELVN ██% $3.78B x 8.3x
Emmaus Life Sciences, Inc. EMMA ██% $820K x x
Enlivex Ltd. ENLV ██% $71M 0.0x 0.0x
Ensysce Biosciences, Inc. ENSC ██% $4M x x
Enanta Pharmaceuticals Inc ENTA ██% $371M x 3.2x
Enveric Biosciences, Inc. ENVB ██% $5M x 1.0x
Evolus, Inc. EOLS ██% $394M x x
Eupraxia Pharmaceuticals Inc. EPRX ██% $380M x 4.6x
Equillium, Inc. EQ ██% $170M x 2.9x
Erasca, Inc. ERAS ██% $6.63B x 16.9x
Ernexa Therapeutics Inc. ERNA ██% $5M x 0.7x
Esperion Therapeutics, Inc. ESPR ██% $799M x x
Eton Pharmaceuticals, Inc. ETON ██% $1.17B x 38.1x
Earth Science Tech, Inc. ETST ██% $36M 7.5x 5.2x
Evofem Biosciences, Inc. EVFM ██% $1M x x
Evommune, Inc. EVMN ██% $409M x 1.3x
Edgewise Therapeutics, Inc. EWTX ██% $4.22B x 8.6x
Fortress Biotech, Inc. FBIO ██% $111M 0.9x 0.7x
Fibrobiologics, Inc. FBLG ██% $4M x 1.4x
Forte Biosciences, Inc. FBRX ██% $1.22B x 29.0x
Foghorn Therapeutics Inc. FHTX ██% $298M x x
Filana Therapeutics, Inc. FLNA ██% $43M x 0.6x
Faeth Therapeutics, Inc. FTH ██% $716M x x
Fulcrum Therapeutics, Inc. FULC ██% $248M x 0.7x
Galectin Therapeutics Inc GALT ██% $229M x x
Gain Therapeutics, Inc. GANX ██% $77M x 5.5x
Greater Cannabis Company, Inc. GCAN ██% $260K x x
Cytomed Therapeutics Ltd GDTC ██% $12M x x
Geron Corp GERN ██% $946M x 4.1x
Gh Research Plc GHRS ██% $1.71B x x
Galmed Pharmaceuticals Ltd. GLMD ██% $3M x 0.2x
Greenwich Lifesciences, Inc. GLSI ██% $190M x 36.1x
Genelux Corp GNLX ██% $133M x 5.8x
Genprex, Inc. GNPX ██% $4M x 0.2x
Gossamer Bio, Inc. GOSS ██% $70M x x
Geovax Labs, Inc. GOVX ██% $4M x 8.9x
Structure Therapeutics Inc. GPCR ██% $3.49B x 2.4x
Grace Therapeutics, Inc. GRCE ██% $39M x 0.6x
Gri Bio, Inc. GRI ██% $3M x 0.3x
Galera Therapeutics, Inc. GRTX ██% $3.38B 22.7x 4646.0x
Gsk Plc GSK ██% $101.62B x x
Gt Biopharma, Inc. GTBP ██% $12M x 1.6x
Gyre Therapeutics, Inc. GYRE ██% $670M x 6.6x
Hutchmed (China) Ltd HCM ██% $1.88B 2.1x 1.5x
Hcw Biologics Inc. HCWB ██% $5M x 0.8x
Cybin Inc. HELP ██% $479M x x
Hepion Pharmaceuticals, Inc. HEPA ██% $1M x 0.7x
Vyome Holdings, Inc HIND ██% $15M x 2.2x
Hookipa Pharma Inc. HOOK ██% $14M x 0.4x
Werewolf Therapeutics, Inc. HOWL ██% $17M x 1.4x
Harmony Biosciences Holdings, Inc. HRMY ██% $2.07B 14.2x 2.3x
Heron Therapeutics, Inc. /De/ HRTX ██% $87M x 9.6x
Hst Global, Inc. HSTC ██% $99M x 79.9x
Tuhura Biosciences, Inc./Nv HURA ██% $137M x 5.9x
Mindwalk Holdings Corp. HYFT ██% $55M x x
Hyperion Defi, Inc. HYPD ██% $40M x 0.7x
Ibio, Inc. IBIO ██% $70M x 0.9x
Impact Biomedical Inc. IBO ██% $46M x 4.0x
Ideaya Biosciences, Inc. IDYA ██% $3.18B x 3.4x
Inflarx N.V. IFRX ██% $255M x x
Igc Pharma, Inc. IGC ██% $27M x 4.4x
Immutep Ltd IMMP ██% $57M x x
Immix Biopharma, Inc. IMMX ██% $626M x 7.4x
Immunome Inc. IMNM ██% $2.49B x 4.2x
Imunon, Inc. IMNN ██% $7M x 1.9x
Immuron Ltd IMRN ██% $9M x x
Immuneering Corp IMRX ██% $284M x 1.4x
Immunic, Inc. IMUX ██% $195M x 1.3x
Integrated Biopharma Inc INBP ██% $5M x 0.3x
Indaptus Therapeutics, Inc. INDP ██% $369M x 295.8x
Indivior Pharmaceuticals, Inc. INDV ██% $5.02B 19.9x x
Inmed Pharmaceuticals Inc. INM ██% $10M x 1.4x
Inovio Pharmaceuticals, Inc. INO ██% $84M x 13.8x
Insmed Inc INSM ██% $23.26B x 33.0x
Inhibitor Therapeutics, Inc. INTI ██% $15M x x
Innoviva, Inc. INVA ██% $1.56B 3.1x 1.2x
Io Biotech, Inc. IOBTQ ██% $70K x 0.1x
Ionis Pharmaceuticals Inc IONS ██% $9.27B x 18.9x
Opus Genetics, Inc. IRD ██% $241M x x
Disc Medicine, Inc. IRON ██% $2.90B x 4.2x
Ironwood Pharmaceuticals Inc IRWD ██% $624M 6.1x x
International Stem Cell Corp ISCO ██% $2M x x
Inventiva S.A. IVA ██% $1.07B x x
Incannex Healthcare Inc. IXHL ██% $38M x 0.5x
Jaguar Health, Inc. JAGX ██% $5M x x
Janux Therapeutics, Inc. JANX ██% $957M x 1.0x
Jazz Pharmaceuticals Plc JAZZ ██% $15.78B 534.9x 3.5x
Jade Biosciences, Inc. JBIO ██% $1.19B x 4.0x
Johnson & Johnson JNJ ██% $624.17B 29.7x 7.4x
Jupiter Neurosciences, Inc. JUNS ██% $6M x x
Kala Bio, Inc. KALA ██% $11M x 1.1x
Kalvista Pharmaceuticals, Inc. KALV ██% $1.38B x x
Kairos Pharma, Ltd. KAPA ██% $6M x 1.2x
Kaya Holdings, Inc. KAYS ██% $140K x x
Kamada Ltd KMDA ██% $401M x x
Kiniksa Pharmaceuticals International, Plc KNSA ██% $4.82B 66.0x 8.0x
Kiora Pharmaceuticals Inc KPRX ██% $10M x 0.7x
Karyopharm Therapeutics Inc. KPTI ██% $160M x x
Keros Therapeutics, Inc. KROS ██% $200M x 0.7x
Korro Bio, Inc. KRRO ██% $166M x 1.4x
Pasithea Therapeutics Corp. KTTA ██% $16M x 0.3x
Kura Oncology, Inc. KURA ██% $928M x 8.6x
Kyntra Bio, Inc. KYNB ██% $29M 0.2x x
Standard Biotools Inc. LAB ██% $343M 4.4x 0.6x
Lb Pharmaceuticals Inc LBRX ██% $993M x 2.6x
Legend Biotech Corp LEGN ██% $4.55B x x
Lexaria Bioscience Corp. LEXX ██% $14M x 3.0x
Lifecore Biomedical, Inc. \De\ LFCR ██% $166M x x
Lifevantage Corp LFVN ██% $79M 10.0x 2.4x
Ligand Pharmaceuticals Inc LGND ██% $6.05B 39.4x 6.1x
Longeveron Inc. LGVN ██% $19M x 1.2x
Lianbio LIANY ██% $12M x 0.1x
Lftd Partners Inc. LIFD ██% $3M x 0.4x
Lipella Pharmaceuticals Inc. LIPO ██% $150K x 0.1x
Lite Strategy, Inc. LITS ██% $35M x 0.6x
Lixte Biotechnology Holdings, Inc. LIXT ██% $120M x 15.2x
Lakefront Biotherapeutics Nv LKFT ██% $1.85B x x
Eli Lilly & Co LLY ██% $1.06T 42.0x 34.0x
Lunai Bioworks Inc. LNAI ██% $11M x x
Lipocine Inc. LPCN ██% $16M x 0.7x
Liquidia Corp LQDA ██% $7.86B 352.5x 72.4x
Larimar Therapeutics, Inc. LRMR ██% $417M x 2.6x
Lisata Therapeutics, Inc. LSTA ██% $19M x 1.8x
Lantern Pharma Inc. LTRN ██% $32M x 9.4x
Lexicon Pharmaceuticals, Inc. LXRX ██% $979M x 4.8x
Lyell Immunopharma, Inc. LYEL ██% $298M x 1.1x
Maia Biotechnology, Inc. MAIA ██% $78M x 2.8x
Veradermics, Inc MANE ██% $4.84B x 12.4x
Mustang Bio, Inc. MBIO ██% $4M x 0.5x
Moleculin Biotech, Inc. MBRX ██% $15M x 1.0x
Mbx Biosciences, Inc. MBX ██% $3.02B x 6.9x
Seres Therapeutics, Inc. MCRB ██% $50M x 1.9x
Medicus Pharma Ltd. MDCX ██% $22M x 16.4x
Madrigal Pharmaceuticals, Inc. MDGL ██% $12.52B x 23.0x
Macrogenics Inc MGNX ██% $255M x 12.0x
Mira Pharmaceuticals, Inc. MIRA ██% $39M x 4.2x
Mirum Pharmaceuticals, Inc. MIRM ██% $6.97B x 28.7x
Milestone Pharmaceuticals Inc. MIST ██% $141M x 3.9x
Moonlake Immunotherapeutics MLTX ██% $1.62B x 6.4x
Mineralys Therapeutics, Inc. MLYS ██% $2.23B x 3.5x
Mannkind Corp MNKD ██% $1.20B x x
Medicinova Inc MNOV ██% $64M x 1.6x
Monopar Therapeutics MNPR ██% $708M x 5.2x
Maplight Therapeutics, Inc. MPLT ██% $1.59B x 4.0x
Mereo Biopharma Group Plc MREO ██% $46M x 1.4x
Merck & Co., Inc. MRK ██% $322.55B 36.1x 7.0x
Marker Therapeutics, Inc. MRKR ██% $21M x 1.5x
Maravai Lifesciences Holdings, Inc. MRVI ██% $2.60B x 12.3x
Satellos Bioscience Inc. MSLE ██% $200M x x
Matinas Biopharma Holdings, Inc. MTNB ██% $2M x 0.5x
Metavia Inc. MTVA ██% $8M x 0.9x
Newamsterdam Pharma Co N.V. NAMS ██% $3.56B x 5.4x
Natures Sunshine Products Inc NATR ██% $360M 18.1x 2.2x
Novabridge Biosciences NBP ██% $205M x 0.8x
Nanobiotix S.A. NBTX ██% $1.91B x x
Newcelx Ltd. NCEL ██% $20M x 37.7x
Nucana Plc NCNA ██% $6M x x
Minerva Neurosciences, Inc. NERV ██% $195M x x
Neuphoria Therapeutics Inc. NEUP ██% $21M x 0.7x
Neurogene Inc. NGNE ██% $710M x 3.0x
Nika Pharmaceuticals, Inc NIKA ██% $806M x x
Nektar Therapeutics NKTR ██% $2.34B x 4.1x
Nkarta, Inc. NKTX ██% $171M x 0.6x
Nomad Power Solutions, Inc. NMAD ██% $89M x 11.2x
Nanoviricides, Inc. NNVC ██% $33M x 3.6x
Nurix Therapeutics, Inc. NRIX ██% $2.46B x 6.1x
Neurosense Therapeutics Ltd. NRSN ██% $24M x x
Nrx Pharmaceuticals, Inc. NRXP ██% $176M x x
Nasus Pharma Ltd NSRX ██% $36M x 13.1x
Neonc Technologies Holdings, Inc. NTHI ██% $90M x x
Nuvation Bio Inc. NUVB ██% $2.25B x 7.0x
Nuvalent, Inc. NUVL ██% $9.75B x 8.3x
Nuvectis Pharma, Inc. NVCT ██% $635M x 44.7x
Novartis Ag NVS ██% $297.94B x x
Northwest Biotherapeutics Inc NWBO ██% $273M x x
Nextcure, Inc. NXTC ██% $17M x 0.6x
Nexentis Technologies Inc. NXTS ██% $3M x 0.2x
Ocular Therapeutix, Inc OCUL ██% $1.89B x 3.2x
Oragenics Inc OGEN ██% $2M x 0.4x
Organigram Global Inc. OGI ██% $130M x x
Organon & Co. OGN ██% $3.56B 14.5x 3.9x
Onkure Therapeutics, Inc. OKUR ██% $170M x 0.9x
Olema Pharmaceuticals, Inc. OLMA ██% $1.03B x 2.1x
Omeros Corp OMER ██% $740M 8.6x x
Beone Medicines Ltd. ONC ██% $33.90B 66.1x 7.1x
Onconetix, Inc. ONCO ██% $3M x 0.3x
Oncolytics Biotech Inc ONCY ██% $99M x x
Opko Health, Inc. OPK ██% $888M x 0.7x
Organogenesis Holdings Inc. ORGO ██% $313M 115.0x 1.3x
Oric Pharmaceuticals, Inc. ORIC ██% $1.13B x 2.7x
Oruka Therapeutics, Inc. ORKA ██% $5.55B x 11.4x
Oramed Pharmaceuticals Inc. ORMP ██% $170M 1.6x 0.7x
Os Therapies Inc OSTX ██% $61M x x
Oncotelic Therapeutics, Inc. OTLC ██% $13M x 0.1x
Ovid Therapeutics Inc. OVID ██% $401M x 2.0x
One World Products, Inc. OWPC ██% $110K x x
Phibro Animal Health Corp PAHC ██% $1.38B 14.5x 3.8x
Prestige Consumer Healthcare Inc. PBH ██% $2.37B 12.5x 1.3x
Psyence Biomedical Ltd. PBM ██% $11M x x
Puma Biotechnology, Inc. PBYI ██% $408M 16.7x 3.2x
Pacira Biosciences, Inc. PCRX ██% $1.02B 198.4x 1.6x
Processa Pharmaceuticals, Inc. PCSA ██% $8M x 3.0x
Procyon Corp PCYN ██% $2M x 1.0x
Pds Biotechnology Corp PDSB ██% $39M x 10.1x
Pepgen Inc. PEPG ██% $145M x 1.1x
Pfizer Inc PFE ██% $142.33B 19.0x 1.6x
Precigen, Inc. PGEN ██% $1.97B x 97.4x
Phathom Pharmaceuticals, Inc. PHAT ██% $922M x x
Phio Pharmaceuticals Corp. PHIO ██% $12M x 0.8x
Pharvaris N.V. PHVS ██% $2.32B x x
Protokinetix, Inc. PKTX ██% $3M x 10.3x
Pliant Therapeutics, Inc. PLRX ██% $67M x 0.4x
Polaryx Therapeutics, Inc. PLYX ██% $100M x 40.2x
Polomar Health Services, Inc. PMHS ██% $2M x x
Promis Neurosciences Inc. PMN ██% $113M x 1.9x
Pmv Pharmaceuticals, Inc. PMVP ██% $71M x 0.8x
Purple Biotech Ltd. PPBT ██% $1M x x
Propanc Biopharma, Inc. PPCB ██% $3M x 0.3x
Praxis Precision Medicines, Inc. PRAX ██% $8.98B x 6.4x
Prf Technologies Ltd. PRFX ██% $4M x 0.4x
Perrigo Co Plc PRGO ██% $1.39B x 0.6x
Prelude Therapeutics Inc PRLD ██% $324M x 5.4x
Prophase Labs, Inc. PRPH ██% $840K x 0.1x
Proqr Therapeutics N.V. PRQR ██% $253M x x
Prothena Corp Public Ltd Co PRTA ██% $453M x 1.5x
Ptc Therapeutics, Inc. PTCT ██% $6.50B x x
Protagonist Therapeutics, Inc PTGX ██% $8.70B x 13.3x
Protagenic Therapeutics, Inc.\New PTIX ██% $420K x x
Palatin Technologies Inc PTN ██% $14M x 1.4x
Petros Pharmaceuticals, Inc. PTPI ██% $170K 0.0x 0.1x
Pulmatrix, Inc. PULM ██% $6M x 1.8x
Provectus Biopharmaceuticals, Inc. PVCT ██% $26M x x
Palvella Therapeutics, Inc. PVLA ██% $2.05B x 8.8x
Pyxis Oncology, Inc. PYXS ██% $168M x 5.4x
Quoin Pharmaceuticals, Ltd. QNRX ██% $9M x 1.0x
Quantum Biopharma Ltd. QNTM ██% $21M x x
Q32 Bio Inc. QTTB ██% $457M 13.7x 9.9x
Quantum Cyber N.V. QUCY ██% $25M x 5.5x
Uniqure N.V. QURE ██% $2.49B x 16.6x
Radiopharm Theranostics Ltd RADX ██% $34M x x
Rani Therapeutics Holdings, Inc. RANI ██% $122M x 4.3x
Rapport Therapeutics, Inc. RAPP ██% $1.98B x 4.2x
Ultragenyx Pharmaceutical Inc. RARE ██% $2.66B x x
Rocket Pharmaceuticals, Inc. RCKT ██% $358M x 1.5x
Arcus Biosciences, Inc. RCUS ██% $3.73B x 7.1x
Dr Reddys Laboratories Ltd RDY ██% $9.85B x x
Regeneron Pharmaceuticals, Inc. REGN ██% $67.80B 15.3x 2.2x
Revelation Biosciences, Inc. REVB ██% $4M x 0.3x
Rafael Holdings, Inc. RFL ██% $107M x 1.4x
Regen Biopharma Inc RGBP ██% $80K x x
Rigel Pharmaceuticals Inc RIGL ██% $678M 1.9x 1.7x
Rocket One Inc. RKTO ██% $19M x 4.5x
Relmada Therapeutics, Inc. RLMD ██% $546M x 2.5x
Rallybio Corp RLYB ██% $87M x 1.7x
Retrieve Medical Holdings, Inc. RMHI ██% $25M x x
Rockwell Medical, Inc. RMTI ██% $26M x 0.7x
Cartesian Therapeutics, Inc. RNAC ██% $226M x x
Transcode Therapeutics, Inc. RNAZ ██% $7M x 5.5x
Rein Therapeutics, Inc. RNTX ██% $68M x 5.9x
Renovorx, Inc. RNXT ██% $39M x 3.4x
Roivant Sciences Ltd. ROIV ██% $25.28B x 5.6x
Royalty Pharma Plc RPRX ██% $33.99B 41.1x 4.9x
Rest Ez Inc. RTEZ ██% $1.93B x x
Reviva Pharmaceuticals Holdings, Inc. RVPH ██% $6M x 0.4x
Revium Rx. RVRC ██% $101M x 16.5x
Rhythm Pharmaceuticals, Inc. RYTM ██% $7.03B x 57.2x
Rezolute, Inc. RZLT ██% $511M x 4.4x
Sunshine Biopharma Inc. SBFM ██% $3M x 0.1x
Scienture Holdings, Inc. SCNX ██% $16M x 0.2x
Scynexis Inc SCYX ██% $315M x 7.6x
Stablecoin Development Corp SDEV ██% $30M 0.1x 0.2x
Schrodinger, Inc. SDGR ██% $1.12B x 3.6x
Septerna, Inc. SEPN ██% $1.50B x 4.0x
Serina Therapeutics, Inc. SER ██% $31M x 1.8x
Sagimet Biosciences Inc. SGMT ██% $433M x 4.2x
Shuttle Pharmaceuticals Holdings, Inc. SHPH ██% $2M x 0.5x
Siga Technologies Inc SIGA ██% $226M 11.2x 1.5x
Silo Pharma, Inc. SILO ██% $5M x 0.9x
Sionna Therapeutics, Inc. SION ██% $1.99B x 6.9x
Skinvisible, Inc. SKVI ██% $1M x x
Skye Bioscience, Inc. SKYE ██% $24M x 2.6x
Sol-Gel Technologies Ltd. SLGL ██% $261M x 11.5x
Silence Therapeutics Plc SLN ██% $541M x 11.0x
Sellas Life Sciences Group, Inc. SLS ██% $2.24B x 20.8x
Summit Therapeutics Inc. SMMT ██% $11.88B x 18.9x
Semnur Pharmaceuticals, Inc. SMNR ██% $157M x x
Syndax Pharmaceuticals Inc SNDX ██% $1.88B x 45.1x
Soligenix, Inc. SNGX ██% $5M x 1.8x
Faeth Therapeutics, Inc. SNSE ██% $31M x x
Sanofi SNY ██% $103.79B x x
Spruce Biosciences, Inc. SPRB ██% $124M x 3.6x
Scisparc Ltd. SPRC ██% $3M x x
Spero Therapeutics, Inc. SPRO ██% $67M 4.4x 1.3x
Ars Pharmaceuticals, Inc. SPRY ██% $596M x 9.7x
Sarepta Therapeutics, Inc. SRPT ██% $1.68B 25.8x 1.1x
Stoke Therapeutics, Inc. STOK ██% $1.85B x 4.7x
Shattuck Labs, Inc. STTK ██% $677M x 7.1x
Supernus Pharmaceuticals, Inc. SUPN ██% $2.74B x 2.5x
Savara Inc SVRA ██% $1.18B x 6.7x
60 Degrees Pharmaceuticals, Inc. SXTP ██% $4M x 0.8x
Synlogic, Inc. SYBX ██% $8M x 0.6x
Spyre Therapeutics, Inc. SYRE ██% $8.68B x 12.9x
Takeda Pharmaceutical Co Ltd TAK ██% $53.71B x x
Theravance Biopharma, Inc. TBPH ██% $869M 7.6x 3.0x
Alaunos Therapeutics, Inc. TCRT ██% $5M x 3.5x
Telomir Pharmaceuticals, Inc. TELO ██% $80M x 16.1x
Tenax Therapeutics, Inc. TENX ██% $388M x 3.4x
Teva Pharmaceutical Industries Ltd TEVA ██% $36.31B 23.2x 4.4x
Tg Therapeutics, Inc. TGTX ██% $8.50B 18.4x 14.6x
Talphera, Inc. TLPH ██% $69M x 3.7x
Telix Pharmaceuticals Ltd TLX ██% $3.56B x x
Tango Therapeutics, Inc. TNGX ██% $3.96B x 10.1x
Tonix Pharmaceuticals Holding Corp. TNXP ██% $151M x 0.7x
Theriva Biologics, Inc. TOVX ██% $10M x 0.7x
Tempest Therapeutics, Inc. TPST ██% $14M x 16.4x
Entrada Therapeutics, Inc. TRDA ██% $235M x 0.9x
Trevi Therapeutics, Inc. TRVI ██% $2.44B x 14.2x
Turn Therapeutics Inc. TTRX ██% $282M x 46.2x
Tvardi Therapeutics, Inc. TVRD ██% $24M x 1.7x
Travere Therapeutics, Inc. TVTX ██% $5.24B x 53.1x
Therapeuticsmd, Inc. TXMD ██% $24M 133.2x 0.9x
Tyra Biosciences, Inc. TYRA ██% $1.83B x 4.7x
Unicycive Therapeutics, Inc. UNCY ██% $138M x 3.7x
Upstream Bio, Inc. UPB ██% $348M x 1.2x
Urogen Pharma Ltd. URGN ██% $2.07B x x
United Therapeutics Corp UTHR ██% $26.37B 20.5x 4.5x
Valion Bio, Inc. VBIO ██% $920K x 0.1x
Vaccinex, Inc. VCNX ██% $3M x x
Vera Therapeutics, Inc. VERA ██% $2.60B x 5.2x
Sb Technology Holdings, Inc. VGLS ██% $240K x x
Vicapsys Life Sciences, Inc. VICP ██% $47M x x
Viking Therapeutics, Inc. VKTX ██% $4.10B x 8.2x
Vanda Pharmaceuticals Inc. VNDA ██% $322M x 1.2x
Verrica Pharmaceuticals Inc. VRCA ██% $93M x 5.8x
Viridian Therapeutics, Inc.\De VRDN ██% $1.97B x 3.1x
Vireo Growth Inc. VREOD ██% $491M x 1.7x
Vireo Growth Inc. VREOF ██% $491M x 1.7x
Vertex Pharmaceuticals Inc / Ma VRTX ██% $120.24B 27.7x 6.2x
Verastem, Inc. VSTM ██% $543M x 6.6x
Vistagen Therapeutics, Inc. VTGN ██% $9M x 0.3x
Viatris Inc VTRS ██% $19.97B x 1.4x
Vyne Therapeutics Inc. VYNE ██% $620K x 0.0x
Whitehawk Therapeutics, Inc. WHWK ██% $181M x 1.6x
Wave Life Sciences Ltd. WVE ██% $1.11B x 2.2x
Xenetic Biosciences, Inc. XBIO ██% $6M x 0.9x
Xbiotech Inc. XBIT ██% $70M x 0.5x
Exicure, Inc. XCUR ██% $11M x 5.2x
Xenon Pharmaceuticals Inc. XENE ██% $6.32B x 4.7x
Xeris Biopharma Holdings, Inc. XERS ██% $1.45B 120.9x 111.5x
Xilio Therapeutics, Inc. XLO ██% $55M x 0.8x
Xencor Inc XNCR ██% $1.45B x 2.8x
Xoma Royalty Corp XOMA ██% $710M 21.0x 7.7x
Xtl Biopharmaceuticals Ltd XTLB ██% $7M x x
Zenas Biopharma, Inc. ZBIO ██% $1.93B x 5.8x
Zai Lab Ltd ZLAB ██% $2.22B x 3.4x
Zentalis Pharmaceuticals, Inc. ZNTL ██% $317M x 1.7x
Zoetis Inc. ZTS ██% $31.35B 11.9x 9.7x
Zevra Therapeutics, Inc. ZVRA ██% $740M 6.0x 3.6x
Zyversa Therapeutics, Inc. ZVSA ██% $890K x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Gyre Therapeutics, Inc. Stock Forecast

How accurate are Gyre Therapeutics, Inc. stock predictions?

Our AI model shows a 11% Spearman correlation coefficient for CBIO predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Gyre Therapeutics, Inc. stock price forecasts?

Our analysis considers Gyre Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Gyre Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Gyre Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Gyre Therapeutics, Inc. forecasts updated?

Gyre Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Gyre Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...